NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis $3.87 -0.06 (-1.53%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$3.84 -0.02 (-0.65%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Larimar Therapeutics Stock (NASDAQ:LRMR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Larimar Therapeutics alerts:Sign Up Key Stats Today's Range$3.78▼$3.9750-Day Range$3.11▼$4.2652-Week Range$1.61▼$9.50Volume855,271 shsAverage Volume1.33 million shsMarket Capitalization$320.36 millionP/E RatioN/ADividend YieldN/APrice Target$18.43Consensus RatingBuy Company Overview Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. Read More Larimar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreLRMR MarketRank™: Larimar Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 346th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Upside PotentialLarimar Therapeutics has a consensus price target of $18.43, representing about 376.2% upside from its current price of $3.87.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Larimar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Larimar Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.12% of the outstanding shares of Larimar Therapeutics have been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Larimar Therapeutics has recently decreased by 7.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.12% of the outstanding shares of Larimar Therapeutics have been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Larimar Therapeutics has recently decreased by 7.54%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.69 News SentimentLarimar Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Larimar Therapeutics this week, compared to 3 articles on an average week.Search Interest16 people have searched for LRMR on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Larimar Therapeutics' insider trading history. Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LRMR Stock News HeadlinesFY2025 Earnings Estimate for LRMR Issued By Leerink PartnrsSeptember 9 at 2:03 AM | americanbankingnews.comLeerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)August 16, 2025 | theglobeandmail.comTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…September 10 at 2:00 AM | Brownstone Research (Ad)Larimar Therapeutics (LRMR) Gets a Buy from Truist FinancialAugust 16, 2025 | theglobeandmail.comLarimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA FilingAugust 16, 2025 | msn.com3 Best Stocks to Buy Now, 8/15/2025, According to Top AnalystsAugust 15, 2025 | msn.comLarimar Therapeutics Announces $64.4 Million Stock OfferingAugust 15, 2025 | theglobeandmail.comLarimar Therapeutics price target lowered to $18 from $22 at Citizens JMPAugust 15, 2025 | msn.comSee More Headlines LRMR Stock Analysis - Frequently Asked Questions How have LRMR shares performed this year? Larimar Therapeutics' stock was trading at $3.87 at the start of the year. Since then, LRMR shares have increased by 0.0% and is now trading at $3.87. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.06. Who are Larimar Therapeutics' major shareholders? Larimar Therapeutics' top institutional investors include Opaleye Management Inc. (4.96%), Geode Capital Management LLC (1.41%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.37%) and Assenagon Asset Management S.A. (0.40%). Insiders that own company stock include James E Flynn, Michael Celano, Joseph Truitt and Frank E Thomas. View institutional ownership trends. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Larimar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Larimar Therapeutics investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/14/2025Today9/09/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LRMR CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Larimar Therapeutics$18.43 High Price Target$26.00 Low Price Target$10.00 Potential Upside/Downside+376.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-62.92% Return on Assets-53.98% Debt Debt-to-Equity RatioN/A Current Ratio5.46 Quick Ratio5.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.69 per share Price / Book1.44Miscellaneous Outstanding Shares82,780,000Free Float79,053,000Market Cap$320.36 million OptionableOptionable Beta0.91 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:LRMR) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.